Project Grant HT94252410415
Award Date
6/1/24
Completion Date
5/31/27
Dollars Obligated
$890K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
Under the $534,000.00 Project Grant awarded by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420), the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) will conduct research to define the role of the androgen receptor in BRCA1/2-deficient prostate cancer. This translational research aims to improve understanding of disease dependencies and develop new treatment approaches for this challenging cancer type. DFCI, a non-profit hospital...
The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...
The Department of the Army Medical Command awarded a $945,271 project grant to Dana-Farber Cancer Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420). The three-year award beginning July 1, 2021 will fund research to functionally characterize the noncoding genome of metastatic prostate cancer and identify therapeutic vulnerabilities. Dana-Farber will work with Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis to construct a...
The Defense Health Agency has awarded a $1,780,000 Project Grant titled "SUPPORTING UNDERREPRESENTED POPULATIONS IN GENOMICS-BASED CANCER TRIAL ENROLLMENT (SURGE)" to the Dana-Farber Cancer Institute, Inc. in Boston, MA. This award, funded through the Military Medical Research and Development program (CFDA 12.420), will support cancer research focused on improving enrollment of underrepresented populations in genomics-based clinical trials. The grant period runs from July 1, 2024 to...
The Defense Health Agency awarded a $1,290,499 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "ENHANCING THE ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS IN OVARIAN CANCER," will support advanced biomedical research focused on developing innovative approaches to treating ovarian cancer through the enhancement of natural killer cell activity. The award period runs...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...